New research data reveals SaxendaR offers ‘significant improvements’ in cardiometabolic risk factors

Data taken from a long-running clinical trial has revealed that when combined with increased physical activity and a reduced-calorie diet, SaxendaR (liraglutide 3mg) offers “significant improvements” in cardiometabolic risk factors compared to placebo.

The results, which were presented at the Endocrine Society’s 98th Annual Meeting and Expo, and were taken from the 3-year part of the phase 3a SCALE. (Satiety and Clinical Adiposity . Liraglutide Evidence) obesity and prediabetes trial.

The trial looked at data from 2,254 adults with obesity or who were overweight with comorbidities and had prediabetes at baseline. The data, collected over 160 weeks of treatment, saw 1,505 patients treated with SaxendaR (liraglutide 3 mg) in combination with a reduced-calorie diet and increased physical activity. This resulted in improvements in cardiometabolic risk factors (such as blood pressure and cholesterol) compared with the 749 patients who received the placebo.

“We know that weight loss of as little as 5 to 10% in people with obesity can have an impact on cardiometabolic risk factors,” said Dr Ken Fujioka, Scripps Clinic, San Diego, California, US and a SCALE. clinical trial investigator. “This is currently the longest weight-management trial with SaxendaR, and the observed improvements in blood pressure, lipids and waist circumference at three years are encouraging.”

In addition, the three-year part of the SCALE. Obesity and Prediabetes trial met its primary endpoint, demonstrating that continued treatment over three years with SaxendaR, in combination with a reduced-calorie diet and increased physical activity, delayed the onset of type 2 diabetes compared with placebo.